[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
March 21, 2012

Evaluating Sex Differences in Medical Device Clinical TrialsTime for Action

Author Affiliations

Author Affiliations: Department of Medicine (Dr Dhruva), and Women's Cardiovascular Services, School of Medicine, Division of Cardiology (Dr Redberg), University of California, San Francisco. Dr Redberg is also Editor, Archives of Internal Medicine.

JAMA. 2012;307(11):1145-1146. doi:10.1001/jama.2012.254

The safety and effectiveness of medical treatments can differ in men and women for many reasons related to different epidemiologic characteristics, physiology, and body size. In general, women have higher bleeding rates and procedural morbidity and mortality than men, which means that their risk/benefit ratios for many implanted medical devices can differ from men. Therefore, sex-specific safety and effectiveness data are necessary for informed patient decision making. In 2008, the US Food and Drug Administration (FDA) convened 2 workshops on this topic that included multiple stakeholders—patient groups, medical device industry representatives, academia, and government officials. In December 2011, the FDA released a draft guidance informed by these workshops, entitled “Evaluation of Sex Differences in Medical Device Clinical Studies.”1 This document discusses the underrepresentation of women in medical device clinical trials and provides recommendations for increasing enrollment of women and performing sex-specific analyses. A 90-day public comment period began on December 19, 2011.

First Page Preview View Large
First page PDF preview
First page PDF preview
×